Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

San Antonio Breast Cancer Symposium (SABCS) 2024

December 10 - 13, 2024

Trastuzumab deruxtecan
Olaparib
Saruparib
Camizestrant
Capivasertib
Datopotamab deruxecan

pdf

Jacot W et al. Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03)

PDF

Barrios C et al. Real-world treatment for HER2-positive (HER2+) metastatic breast cancer patients and compliance to guideline recommendations: HER2 REAL Brazil cohort

PDF

Nozawa K et al. The effectiveness and the incidence/exacerbation of interstitial lung disease of post-T-DXd treatments in patients with HER2-positive metastatic breast cancer: Japanese multicenter cohort study (EN-SEMBLE)

PDF

Rugo HS et al. Trastuzumab deruxtecan with pembrolizumab in previously treated HER2-expressing advanced or metastatic breast cancer: Interim analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106

PDF

Tsurutani J et al. Real-world analysis of interstitial lung disease in patients with HER2-positive unresectable or recurrent breast cancer treated with trastuzumab deruxtecan: All-patient post-marketing surveillance study in Japan

PDF

Mahtani R et al. HER2+ early breast cancer treatment and outcomes by risk of recurrence: A retrospective US electronic health records study

PDF

Mehta S et al. Incidence and treatment patterns of high-risk HER2+ early stage breast cancer (eBC) patients in the United States (US) community oncology setting

PDF

Jhaveri K et al. Trastuzumab deruxtecan (T-DXd) in combination with capecitabine or capivasertib in patients with HER2-low metastatic breast cancer: A Phase 1b, multicenter, open-label study (DESTINY-Breast08)

PDF

Krishnamurthy S et al. Re-evaluation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 0 or 1+ in metastatic breast cancer (mBC) samples to characterize the proportion of HER2-ultralow (IHC 0 with membrane staining)

PDF

Schildhaus HU et al. Agreement between the DESTINY-Breast04/06 VENTANA 4B5 HER2 IHC clinical trial assay and other comparator assays for HER2-low breast cancer: Overall results of a large-scale, multicenter global ring study

PDF

Henderson M et al. A real-world study of the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC) among racial and ethnic minorities and older populations in the United States

PDF

Marhold M et al. Trastuzumab-deruxtecan in HER2-low metastatic breast cancer patients with newly diagnosed or progressing brain metastases with or without type II leptomeningeal disease: The TUXEDO-4 phase II trial

PDF

Harbeck N et al. Effects of trastuzumab deruxtecan on health-related quality of life and neurological function in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 results

PDF

Bardia A et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: an additional analysis from DESTINY-Breast06

PDF

Garber J et al - OlympiA- Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow.

PDF

Ru M et al - Adverse events in routine real-world clinical practice in patients with HER2-negative early breast cancer according to BRCA status: a retrospective observational study using artificial intelligence in Spain

PDF

Lynce F et al - Real-world clinical outcomes of patients with HER2- BRCAm early breast cancer treated with adjuvant capecitabine

PDF

Mishkin K et al - BRCA genetic testing and treatment patterns for patients with early-stage HER2-negative breast cancer in the United States (U.S.) community setting, 2016–2022.

PDF

Mishkin K et al - Real-world characteristics and BRCA testing among HER2- early breast cancer patients receiving olaparib or other adjuvant therapy in the US community oncology setting

PDF

Sardesai S et al - Real-world demographics, clinical characteristics, and treatment patterns among US patients with HER2-negative early breast cancer and germline BRCA mutations since 2021

pdf

A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4/6i plus physician’s choice endocrine therapy or + camizestrant in patients w/ BRCA1/BRCA2/PALB2 mutations & HR+/HER2- advanced breast cancer (EvoPAR-Breast01

pdf

Ruiz-Borrego M et al - Results from SERENA-1 Parts K/L: A Phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive, HER2 negative advanced breast cancer

pdf

Brufsky AM et al - Real-world comparative efficacy of CDK4/6 inhibitors in first-line treatment of HR+/HER2– metastatic breast cancer

pdf

Montero AJ et al - Changing treatment paradigms and unmet needs in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (mBC): Results from health records data

pdf

Ros S et al - The addition of ribociclib, palbociclib or abemaciclib to the next generation oral SERD, camizestrant, delivers greater anti-tumour efficacy in a range of ESR1wt and ESR1m breast PDX models

pdf

Cortés J et al, Prevalence of PIK3CA/AKT1/PTEN and other genomic alterations in primary and recurrent tumor tissue: Exploratory analysis from the Phase 3 CAPItello-291 clinical trial

pdf

Jhaveri K et al. Capivasertib-fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer who had relapsed or progressed during or after aromatase inhibitor treatment: Exploratory analysis of PTEN deficiency by IHC from the phase III CAPItello-291 trial

pdf

Traina T et al. Real-world treatment patterns and clinical outcomes for patients with metastatic triple-negative breast cancer (mTNBC) in the United States: An electronic health records observational study.

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização